OGN News and Press, Organon & Co. From 09/16/22

Summary A high level of restructuring is occurring with the Healthcare industry’s largest constituents. Most restructuring is taking the form of splits or spin-offs, but not all incidences look beneficial. This article will summarize coming transactions and provide comm...

The shares of Organon & Co. ( NYSE: OGN ) traded higher in the morning hours Tuesday after Piper Sandler upgraded the Merck ( MRK ) spinoff, citing less than expected sales decline in the company’s Established Brands (EB) division. However, analysts David Amse...

Summary Organon has seen a real struggle in its first year on its own as a publicly listed business. Lack of growth was anticipated, yet the extent of margin pressure has been unexpected. With net debt flattish, leverage ratios have only increased, creating few triggers in the...

Development-stage biotech Oragenics, Inc. ( NYSE: OGN ) announced initial data on Wednesday from an ongoing Good Laboratory Practice (GLP) toxicology study for NT-CoV2-1, an intranasal COVID-19 vaccine candidate. The data, generated from a rabbit model, indicate a safety p...

Pfizer's net income was $7,864 million in Q2 2022, up 131.8% QoQ. AbbVie's net income was $924 million in Q2 2022, up 20.6% year-on-year. It is unlikely that the Inflation Reduction Act will have a strong impact on the financial position of Pfizer and AbbVie. Both companies ha...

The U.S. Food and Drug Administration (FDA) approved a citrate-free, high-concentration (100 mg/mL) formulation of Samsung Bioepis and Organon's ( NYSE: OGN ) Hadlima, a biosimilar to AbbVie's ( ABBV ) blockbuster arthritis/psoriasis therapy Humira (adalimuma...

Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced the U.S. Food and Drug Administration (FDA) has approved the citrate-free, high-concentration (100 mg/mL) formulation of HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA ® (adalimumab)...

Pharmaceutical/biotechnology is the subsector with the highest value and quality scores. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. 10 stocks cheaper than their peers in August. This monthly article series shows a dashboa...

Kahn Brothers' 13F portfolio value decreased from ~$788M to ~$743M this quarter. New York Community Bancorp, Citigroup, VOXX International, and ViewRay were increased while decreasing Patterson-UTI Energy during the quarter. The portfolio continues to be very concentrated with the...

BofA Securities has downgraded Organon ( NYSE: OGN ) to neutral from buy following the company's recent Q2 2022 results as there are better opportunities for upside in pharma. The firm also lowered its price target to $37 from $40 (~14% upside based on Thursday's close...